Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer

Fig. 1

Abnormal levels of m6A modified mRNA are related to multiple pathways in breast cancer. a The volcano plot of differential methylation sites of breast cancer tissues compared with adjacent normal tissues, n = 2, |log2(fold change)|> 1 and p value < 0.05. b Venn diagram (left panel) of common (intersection region) and unique peaks (non-intersection region) of breast cancer tissue compared with adjacent normal tissue, |log2(fold change)|> 1 and p value < 0.05. The gene region (right panel) annotated with different peaks of breast cancer tissue compared with adjacent normal tissue, |log2(fold change)|> 1 and p value < 0.05. c Differential m6A and differential gene expression combined analysis diagram. Blue dots represent transcripts with significantly downregulated and upregulated m6A expression, red dots represent transcripts with significantly upregulated expression and upregulated m6A expression, green dots represent transcripts with significantly downregulated and downregulated m6A expression, and yellow dots represent transcripts with significantly upregulated and downregulated m6A expression. d Functional enrichment of differentially expressed genes with different m6A methylation sites (left panel). The KEGG pathway enrichment bubble map of differential m6A methylation and differentially expressed genes (right panel). e List of LATS1 containing transcripts of differentially methylated sites (upper panel) in breast cancer tissues compared with adjacent normal tissues, n = 2, |log2(fold change)|> 1 and p value < 0.05. SRAMP prediction results of m6A sites on LATS1 (lower panel). f m6A2Target prediction results of m6A proteins related to LATS1

Back to article page